Strives to change the cancer treatment model in Hong Kong and ready to tap into tremendous opportunities in the Greater Bay Area.
ACT Genomics, a leading cancer precision treatment solution provider, opened its third Next Generation Sequencing (NGS) laboratory in Asia at Hong Kong Science Park, an innovation and technology centre spearheaded by the Hong Kong Science and Technology Parks Corporation. (HKSTP) The opening ceremony was officiated by Ms Annie Choi, Commissioner for Innovation and Technology; Mr Albert WONG, Chief Executive Officer of HKSTP; together with Dr Chen Hua Chien, Chief Executive Officer, Dr Chen Shu Jen, Chief Scientific Officer, and Mr Victor Chan, Chief Financial Officer of ACT Genomics.
Founded in Taiwan in 2014, ACT Genomics provides cancer patients with personalized genomic information-based treatment plans through its cutting-edge NGS platform, medical reporting, and integrated services. The platform can detect multiple genomic alterations using a single tissue sample within a test run. When used together with bioinformatics analysis tools, curated proprietary medical informatic databases and data visualization technologies, it can match identified mutations with approved and targeted therapies in clinical trials, thus facilitating precise treatments. Apart from the laboratory in Hong Kong, the Group also has laboratories in Taiwan and Japan serving the Asia market. With more than 7,800 samples sequenced, the Group has built a comprehensive cancer genomic database in Asia covering 20 different types of cancer.
The new NGS laboratory of the Group in Hong Kong is equipped with dual sequencing platforms, which boast quicker turnaround time and high throughput. With roughly 7,000 square feet the laboratory is supported by workforce of about 40 responsible for sales, medical science and research and laboratory work. It is designed and built to serve the clinical, pharmaceutical and research communities in the city and Asia, and aspires to capture the opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area in the future.
ACT Genomics believes that the Hong Kong Science Park, dedicated to supporting deep tech enterprises and availing to them all necessary facilities and services, making it an ideal location for ACT Genomics’ new NGS laboratory. In addition to having the support of quality infrastructure, the thriving biotech community there will also present to ACT Genomics abundant collaboration and co-innovation opportunities. Moreover, this Hong Kong laboratory will serve as the ACT Genomics’ corporate finance headquarters, helping it foster closer ties with the investment community in the city deemed an international financial hub. [APBN]